Alimera Announces Reimbursement of Uveitis Indication Granted for Iluvien in the Czech Republic

Alimera Sciences announced that Alimera Sciences Europe Limited, its Ireland-based European subsidiary, has been granted reimbursement for Iluvien (fluocinolone acetonide intravitreal implant) 0.19 mg sustained release intravitreal implant for noninfectious uveitis, through its distribution partner, Medis Pharmaceutical Company. After the National Health Insurance Fund (NHIF) agreed to the unmet need and budget impact, the State Institute for Drug Control (SUKL) in the Czech Republic issued a positive decision that Iluvien is reimbursed for the prevention of the relapse in adult patients with recurrent noninfectious uveitis affecting the posterior segment of the eye.

“We are pleased to gain this reimbursement in the Czech Republic and thankful to our partner Medis for this achievement and for their upcoming launch,” said Rick Eiswirth, President and Chief Executive Officer of Alimera. “The positive assessment coming from SUKL and the recognition of this unmet need by the NHIF will help physicians in the Czech Republic prevent the relapse of recurrent noninfectious uveitis affecting the posterior segment.”

The Iluvien sustained release intravitreal implant is indicated in Europe for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies and for prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS).